Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pneumothorax-II01:27

Pneumothorax-II

104
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
104
Pneumothorax-I01:26

Pneumothorax-I

154
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
154

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Endobronchial ultrasound-guided mediastinal cryobiopsy: A retrospective study from two tertiary care centres in north-central India.

Lung India : official organ of Indian Chest Society·2026
Same author

Primary ovarian diffuse large B-cell lymphoma.

BMJ case reports·2026
Same author

Locoregional and symptomatic response to neoadjuvant dual HER2 blockade with chemotherapy in HER2-positive breast cancer: a pilot study.

Anti-cancer drugs·2025
Same author

Efficacy of pulmonary rehabilitation on patient-reported outcomes in interstitial lung disease: A quasi-experimental study.

Respiratory medicine·2025
Same author

Role of oscillometry to diagnose obstructive airway diseases in patients who are unable to perform spirometry correctly.

Medical journal, Armed Forces India·2025
Same author

Topiramate-induced acute eosinophilic pneumonia.

Drug and therapeutics bulletin·2025

相关实验视频

Updated: May 7, 2025

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
06:52

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

17.1K

杜塞塔克塞尔诱导的肺损伤

Amit Singh Vasan1, Gurjeet Singh Chowdhary2, Indramani Pandey3

  • 1Graded Specialist (Pulmonary Medicine), Command Hospital (Western Command), Chandimandir, Haryana, India.

Medical journal, Armed Forces India
|December 30, 2024
PubMed
概括

多塞塔克塞尔可以引起罕见但致命的间歇性肺病 (ILD). 这一病例系列显示了三名患有肺毒性的患者,他们使用类固醇得到改善,与其他研究中的严重结果不同.

关键词:
多塞塔克塞尔 (Docetaxel) 是一种药物诱导的肺炎是药物引起的.组织肺炎的组织纳税人就是纳税人.

更多相关视频

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.5K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.9K

相关实验视频

Last Updated: May 7, 2025

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
06:52

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

17.1K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.5K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.9K

科学领域:

  • 在瘤学瘤学.
  • 肺部病理学 肺部病理学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 多塞塔克塞尔是一种化疗剂,用于治疗各种癌症,包括乳腺癌,肺癌和前列腺癌.
  • 杜塞塔塞尔诱导的间歇性肺病 (ILD) 是一种罕见但严重的不良事件,与高死亡率有关.
  • 识别和管理ILD对于患者的治疗结果至关重要.

研究的目的:

  • 报告一系列病例,其中三名患者在多塞塔克塞尔 (docetaxel) 后出现肺毒性.
  • 为了突出类固醇治疗在管理多塞塔克塞尔诱导的ILD中的有效性.
  • 为了将这些结果与之前报告的需要呼吸辅助的严重病例进行对比.

主要方法:

  • 对三名患者的回顾性审查,在多塞塔克塞尔治疗后出现肺毒性.
  • 对临床表现,治疗干预措施和患者结果的分析.
  • 与现有的关于多塞塔塞尔诱导ILD的文献进行比较.

主要成果:

  • 这三名患者在多塞塔克塞尔给药后都出现了肺毒性.
  • 患者对提醒类固醇治疗和停止使用多塞塔塞尔的治疗做出了积极反应.
  • 没有一个患者进展到呼吸衰竭或需要输管,与文献中报道的病例不同.

结论:

  • 多塞塔克塞尔可以引起间歇性肺病 (ILD),这是一个罕见但可能致命的并发症.
  • 早期识别和使用类固醇治疗可能会导致多塞塔塞尔诱导的ILD患者的良好结果.
  • 这一案例系列表明,与之前记录的严重结果相比,类固醇治疗的预后可能更好.